Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T, Naiki T, Sugiyama Y, Nagai T, Iida K, Noda Y, Shimizu N, Tasaki Y, Mimura Y, Okada T, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Etani T, et al. Among authors: hamamoto s. Oncology. 2020;98(12):876-883. doi: 10.1159/000508923. Epub 2020 Aug 28. Oncology. 2020. PMID: 32862183
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: hamamoto s. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Furukawa-Hibi Y, Yasui T. Tomiyama N, et al. Among authors: hamamoto s. Int J Urol. 2023 Sep;30(9):754-761. doi: 10.1111/iju.15198. Epub 2023 May 7. Int J Urol. 2023. PMID: 37150513
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K. Tasaki Y, et al. Among authors: hamamoto s. Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6. Int J Urol. 2023. PMID: 37278575
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: hamamoto s. Asia Pac J Clin Oncol. 2024 Aug;20(4):515-521. doi: 10.1111/ajco.14073. Epub 2024 Apr 29. Asia Pac J Clin Oncol. 2024. PMID: 38682421
Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Furukawa-Hibi Y, Yasui T. Tasaki Y, et al. Among authors: hamamoto s. Transl Androl Urol. 2024 Apr 30;13(4):631-634. doi: 10.21037/tau-23-647. Epub 2024 Apr 12. Transl Androl Urol. 2024. PMID: 38721293 Free PMC article. No abstract available.
361 results